Latest Arena Pharmaceuticals (ARNA) Headlines F
Post# of 71
Posted On: 03/13/2014 5:23:25 AM
Latest Arena Pharmaceuticals (ARNA) Headlines
Financial Results Releases and Schedules, Clinical Study Results, Partnerships, and Senior-Level Appointments - Analyst Notes on Arena, Horizon Pharma, Enanta, Vanda, and PTC
PR Newswire - Wed Mar 05, 2:30PM CST
Editor Note: For more information about this release, please scroll to bottom.
Biotech Stock Roundup: InterMune Grabs Headlines with Impressive Data - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Mar 05, 9:58AM CST
Last week saw companies like Medivation, Arena and VIVUS reporting fourth quarter results. But, the spotlight remained on InterMune with its late-stage data on Esbriet.
Have Anti-Obesity Drug Prospects Finally Gone Belly-Up?
Sean Williams, The Motley Fool - Motley Fool - Tue Mar 04, 1:05PM CST
On paper, it just makes so much sense that physicians and patients would turn to chronic weight control management therapies offered by VIVUS and Arena Pharmaceuticals as in addition to proper diet and exercise to lose weight. But paper is...
Is A Short Squeeze Ahead for Arena Pharmaceuticals (ARNA)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 04, 8:23AM CST
Is A Short Squeeze Ahead for Arena Pharmaceuticals (ARNA)?
Company news for March 03, 2014 - Corporate Summary
Zacks Equity Research - Zacks Investment Research - Mon Mar 03, 9:06AM CST
Companies in the News are: ARNA,MNST,KBR,CRM
3 Important Investing Lessons From the Oscars
David Williamson, The Motley Fool - Motley Fool - Sun Mar 02, 7:10PM CST
Football season is over, which means my wife regained control of our TV remote. This also means, like millions of Americans, I will be watching the 86th Academy Awards tonight. While my taste in film is decidedly more Pacific Rim than Precious ,...
Arena Pharmaceuticals, Inc. Down for No Reason
Brian Orelli, The Motley Fool - Motley Fool - Fri Feb 28, 8:19PM CST
Arena Pharmaceuticals ended down 3.8% Friday after announcing earnings on Thursday night that included a rather paltry $2.3 million in revenue from sales of its obesity drug Belviq. The sales don't seem to justify the downturn. We've known about...
Arena Posts Wider Loss, Misses Ests - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 28, 11:20AM CST
Arena Pharmaceuticals reported net loss per share of 11 cents in the fourth quarter of 2013.
Arena Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2013 Financial Results
PR Newswire - Thu Feb 27, 3:22PM CST
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2013.
Global Obesity Drug Forecast and Market Analysis to 2022 - Market to Reach $8.4 Billion
M2 - Thu Feb 27, 4:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/l5mtst/pharmapoint) has announced the addition of the "PharmaPoint: Obesity - Global Drug Forecast and Market Analysis to 2022" report to their offering. Obesity Therapy Market to Reach $8.4 billion by 2022 Due to the launches of several novel drugs during the next decade, the obesity market will increase from $407m in 2012 to $8.4 billion by 2022, at a Compound Annual Growth Rate (CAGR) of 35.3%, forecasts research and consulting firm The authors. The US, Canada and Japan will have the largest obesity therapy sales by 2022, with shares of $5.3 billion, $702m and $484m, respectively. The obesity space has seen little activity in the past decade due to a pharmacological history of modest efficacy, poor tolerability with dangerous side effects, and limited healthcare coverage, which have all contributed to the commercial failure of anti-obesity drugs. Recently, however, there has been a revival of this market space, as a couple of companies have released drugs that challenge these limitations. The two drugs that will have the greatest impact on the size of the market are Victoza and Belviq. Victoza's advantage, in addition to its efficacy, lies largely in the fact that it is marketed for the treatment of type 2 diabetes by Novo Nordisk. Belviq's advantage lies in its novelty; unlike Vivus' Qsymia and the two drugs being developed by Orexigen, it is a novel molecular entity, rather than a combination of existing therapeutic options. With the changing tide of opinion on the treatment of obesity and the upcoming launches of new drugs and devices, we anticipate that the prescribing of obesity therapies will increase over the next 10 years, boosting the market size, Wong says. Still, there is a lack of reimbursement for obesity drugs in the US and public health systems throughout the rest of the world, which could hinder any further market growth. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Epidemiology 5 Disease Management 6 Competitive Assessment 7 Opportunity and Unmet Need 8 Pipeline Assessment 9 Current and Future Players 10 Market Outlook 11 Appendix Companies Mentioned - Agency for Medical Innovation - Allergan - Apollo Endosurgery - Arena Pharmaceuticals and Eisai - Aspire Bariatrics - Bariatric Solutions - Baronova - BaroSense - BFKW - C.R. Bard - Cousin Biotech - Endalis Laboratory - EndoGastric Solutions - EndoSphere - EnteroMedics - Ethicon Endo-Surgery - GI Dynamics - Helioscopie - IntraPace - Medical Innovation Development - MetaCure - Novo Nordisk - Obalon Therapeutics - Orexigen Therapeutics - ReShape Medical - Roche Holdings - Shionogi - Spatz Medical - Takeda Pharmaceutical Company - ValenTx For more information visit http://www.researchandmarkets.com/research/l5...harmapoint
Biotech Stock Roundup: Isis Soars on Positive Data, Onconova Falls - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Feb 26, 9:26AM CST
Last week was marked by label expansion and mixed results on pipeline candidates.
Arena Pharmaceuticals, Inc. Earnings: What to Expect Thursday
Dan Caplinger, The Motley Fool - Motley Fool - Tue Feb 25, 11:01PM CST
Arena Pharmaceuticals will release its quarterly report on Thursday, and investors are more nervous than ever about the prospects for the maker of obesity drug Belviq. With rival VIVUS having reported another round of disappointing sales of its...
Another Big Failure for VIVUS, Inc.
David Williamson, The Motley Fool - Motley Fool - Tue Feb 25, 4:02PM CST
Vivus Pharmaceuticals is having an absolutely awful day, with the stock down more than 13% after the company reported its Q4 results. The launch of its first-in-class obesity drug Qsymia was very highly anticipated among investors with the market...
Why VIVUS Inc. Shares Slimmed Down
Sean Williams, The Motley Fool - Motley Fool - Tue Feb 25, 11:58AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of VIVUS , a biopharmaceutical company...
Why VIVUS Inc. Is Falling Today
George Budwell, The Motley Fool - Motley Fool - Tue Feb 25, 8:33AM CST
VIVUS reported earnings after the bell yesterday and its shares have been on a roller coaster ride ever since. Immediately following the release, shares rose over 4%, but have now fallen close to 13% in premarket trading this morning. ...
Cheaper Obesity Drugs Available (for Half of Some Americans)
Brian Orelli, The Motley Fool - Motley Fool - Mon Feb 24, 3:48PM CST
Arena Pharmaceuticals and Eisai announced this month that their obesity drug Belviq has broader coverage from insurance plans run by pharmacy benefits manager CVS Caremark . And health-insurer Aetna is also making Belviq available as part of...
The 10 Most Heavily Shorted Bio-Pharma Stocks
at The Street - Mon Feb 24, 9:39AM CST
The No. 1 stock on this list has more than half its float short.
Arterial Thrombosis - Pipeline Review, H2 2013 Research Report
M2 - Mon Feb 24, 3:17AM CST
Research and Markets (http://www.researchandmarkets.com/research/f8f4ch/arterial) has announced the addition of the "Arterial Thrombosis - Pipeline Review, H2 2013" report to their offering. 'Arterial Thrombosis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Arterial Thrombosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Arterial Thrombosis. Scope - A snapshot of the global therapeutic scenario for Arterial Thrombosis. - A review of the Arterial Thrombosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Arterial Thrombosis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction Arterial Thrombosis Overview Therapeutics Development Pipeline Products for Arterial Thrombosis - Overview Late Stage Products Clinical Stage Products Early Stage Products Arterial Thrombosis - Products under Development by Companies Arterial Thrombosis - Therapeutics Assessment Drug Profiles ticagrelor - Drug Profile temanogrel hydrochloride - Drug Profile PZ-128 - Drug Profile BMS-593214 - Drug Profile ER-410660 - Drug Profile E-5539 - Drug Profile Arterial Thrombosis - Recent Pipeline Updates Arterial Thrombosis - Dormant Projects Arterial Thrombosis - Product Development Milestones Featured News & Press Releases List of Tables List of Figures Companies Mentioned Bristol-Myers Squibb Company AstraZeneca PLC Eisai Co., Ltd. Arena Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/f8f4ch/arterial About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
VIVUS, Inc. Earnings: What to Expect Monday
Dan Caplinger, The Motley Fool - Motley Fool - Sat Feb 22, 12:45PM CST
VIVUS will release its quarterly report on Monday, and investors haven't been happy with the way that the obesity-drug maker's stock has performed. Despite the huge potential in the obesity-treatment space that sent shares of VIVUS, Arena...
Biotech Showdown: Arena Pharmaceuticals vs. VIVUS Inc.
George Budwell, The Motley Fool - Motley Fool - Thu Feb 20, 8:59AM CST
The obesity-drug space is turning out to be tough sledding for Arena Pharmaceuticals and VIVUS , with both of their respective FDA approved medications failing to meet market expectations in terms of prescription numbers. As a result, shares of...
Financial Results Releases and Schedules, Clinical Study Results, Partnerships, and Senior-Level Appointments - Analyst Notes on Arena, Horizon Pharma, Enanta, Vanda, and PTC
PR Newswire - Wed Mar 05, 2:30PM CST
Editor Note: For more information about this release, please scroll to bottom.
Biotech Stock Roundup: InterMune Grabs Headlines with Impressive Data - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Mar 05, 9:58AM CST
Last week saw companies like Medivation, Arena and VIVUS reporting fourth quarter results. But, the spotlight remained on InterMune with its late-stage data on Esbriet.
Have Anti-Obesity Drug Prospects Finally Gone Belly-Up?
Sean Williams, The Motley Fool - Motley Fool - Tue Mar 04, 1:05PM CST
On paper, it just makes so much sense that physicians and patients would turn to chronic weight control management therapies offered by VIVUS and Arena Pharmaceuticals as in addition to proper diet and exercise to lose weight. But paper is...
Is A Short Squeeze Ahead for Arena Pharmaceuticals (ARNA)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 04, 8:23AM CST
Is A Short Squeeze Ahead for Arena Pharmaceuticals (ARNA)?
Company news for March 03, 2014 - Corporate Summary
Zacks Equity Research - Zacks Investment Research - Mon Mar 03, 9:06AM CST
Companies in the News are: ARNA,MNST,KBR,CRM
3 Important Investing Lessons From the Oscars
David Williamson, The Motley Fool - Motley Fool - Sun Mar 02, 7:10PM CST
Football season is over, which means my wife regained control of our TV remote. This also means, like millions of Americans, I will be watching the 86th Academy Awards tonight. While my taste in film is decidedly more Pacific Rim than Precious ,...
Arena Pharmaceuticals, Inc. Down for No Reason
Brian Orelli, The Motley Fool - Motley Fool - Fri Feb 28, 8:19PM CST
Arena Pharmaceuticals ended down 3.8% Friday after announcing earnings on Thursday night that included a rather paltry $2.3 million in revenue from sales of its obesity drug Belviq. The sales don't seem to justify the downturn. We've known about...
Arena Posts Wider Loss, Misses Ests - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 28, 11:20AM CST
Arena Pharmaceuticals reported net loss per share of 11 cents in the fourth quarter of 2013.
Arena Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2013 Financial Results
PR Newswire - Thu Feb 27, 3:22PM CST
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2013.
Global Obesity Drug Forecast and Market Analysis to 2022 - Market to Reach $8.4 Billion
M2 - Thu Feb 27, 4:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/l5mtst/pharmapoint) has announced the addition of the "PharmaPoint: Obesity - Global Drug Forecast and Market Analysis to 2022" report to their offering. Obesity Therapy Market to Reach $8.4 billion by 2022 Due to the launches of several novel drugs during the next decade, the obesity market will increase from $407m in 2012 to $8.4 billion by 2022, at a Compound Annual Growth Rate (CAGR) of 35.3%, forecasts research and consulting firm The authors. The US, Canada and Japan will have the largest obesity therapy sales by 2022, with shares of $5.3 billion, $702m and $484m, respectively. The obesity space has seen little activity in the past decade due to a pharmacological history of modest efficacy, poor tolerability with dangerous side effects, and limited healthcare coverage, which have all contributed to the commercial failure of anti-obesity drugs. Recently, however, there has been a revival of this market space, as a couple of companies have released drugs that challenge these limitations. The two drugs that will have the greatest impact on the size of the market are Victoza and Belviq. Victoza's advantage, in addition to its efficacy, lies largely in the fact that it is marketed for the treatment of type 2 diabetes by Novo Nordisk. Belviq's advantage lies in its novelty; unlike Vivus' Qsymia and the two drugs being developed by Orexigen, it is a novel molecular entity, rather than a combination of existing therapeutic options. With the changing tide of opinion on the treatment of obesity and the upcoming launches of new drugs and devices, we anticipate that the prescribing of obesity therapies will increase over the next 10 years, boosting the market size, Wong says. Still, there is a lack of reimbursement for obesity drugs in the US and public health systems throughout the rest of the world, which could hinder any further market growth. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Epidemiology 5 Disease Management 6 Competitive Assessment 7 Opportunity and Unmet Need 8 Pipeline Assessment 9 Current and Future Players 10 Market Outlook 11 Appendix Companies Mentioned - Agency for Medical Innovation - Allergan - Apollo Endosurgery - Arena Pharmaceuticals and Eisai - Aspire Bariatrics - Bariatric Solutions - Baronova - BaroSense - BFKW - C.R. Bard - Cousin Biotech - Endalis Laboratory - EndoGastric Solutions - EndoSphere - EnteroMedics - Ethicon Endo-Surgery - GI Dynamics - Helioscopie - IntraPace - Medical Innovation Development - MetaCure - Novo Nordisk - Obalon Therapeutics - Orexigen Therapeutics - ReShape Medical - Roche Holdings - Shionogi - Spatz Medical - Takeda Pharmaceutical Company - ValenTx For more information visit http://www.researchandmarkets.com/research/l5...harmapoint
Biotech Stock Roundup: Isis Soars on Positive Data, Onconova Falls - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Feb 26, 9:26AM CST
Last week was marked by label expansion and mixed results on pipeline candidates.
Arena Pharmaceuticals, Inc. Earnings: What to Expect Thursday
Dan Caplinger, The Motley Fool - Motley Fool - Tue Feb 25, 11:01PM CST
Arena Pharmaceuticals will release its quarterly report on Thursday, and investors are more nervous than ever about the prospects for the maker of obesity drug Belviq. With rival VIVUS having reported another round of disappointing sales of its...
Another Big Failure for VIVUS, Inc.
David Williamson, The Motley Fool - Motley Fool - Tue Feb 25, 4:02PM CST
Vivus Pharmaceuticals is having an absolutely awful day, with the stock down more than 13% after the company reported its Q4 results. The launch of its first-in-class obesity drug Qsymia was very highly anticipated among investors with the market...
Why VIVUS Inc. Shares Slimmed Down
Sean Williams, The Motley Fool - Motley Fool - Tue Feb 25, 11:58AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of VIVUS , a biopharmaceutical company...
Why VIVUS Inc. Is Falling Today
George Budwell, The Motley Fool - Motley Fool - Tue Feb 25, 8:33AM CST
VIVUS reported earnings after the bell yesterday and its shares have been on a roller coaster ride ever since. Immediately following the release, shares rose over 4%, but have now fallen close to 13% in premarket trading this morning. ...
Cheaper Obesity Drugs Available (for Half of Some Americans)
Brian Orelli, The Motley Fool - Motley Fool - Mon Feb 24, 3:48PM CST
Arena Pharmaceuticals and Eisai announced this month that their obesity drug Belviq has broader coverage from insurance plans run by pharmacy benefits manager CVS Caremark . And health-insurer Aetna is also making Belviq available as part of...
The 10 Most Heavily Shorted Bio-Pharma Stocks
at The Street - Mon Feb 24, 9:39AM CST
The No. 1 stock on this list has more than half its float short.
Arterial Thrombosis - Pipeline Review, H2 2013 Research Report
M2 - Mon Feb 24, 3:17AM CST
Research and Markets (http://www.researchandmarkets.com/research/f8f4ch/arterial) has announced the addition of the "Arterial Thrombosis - Pipeline Review, H2 2013" report to their offering. 'Arterial Thrombosis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Arterial Thrombosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Arterial Thrombosis. Scope - A snapshot of the global therapeutic scenario for Arterial Thrombosis. - A review of the Arterial Thrombosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Arterial Thrombosis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction Arterial Thrombosis Overview Therapeutics Development Pipeline Products for Arterial Thrombosis - Overview Late Stage Products Clinical Stage Products Early Stage Products Arterial Thrombosis - Products under Development by Companies Arterial Thrombosis - Therapeutics Assessment Drug Profiles ticagrelor - Drug Profile temanogrel hydrochloride - Drug Profile PZ-128 - Drug Profile BMS-593214 - Drug Profile ER-410660 - Drug Profile E-5539 - Drug Profile Arterial Thrombosis - Recent Pipeline Updates Arterial Thrombosis - Dormant Projects Arterial Thrombosis - Product Development Milestones Featured News & Press Releases List of Tables List of Figures Companies Mentioned Bristol-Myers Squibb Company AstraZeneca PLC Eisai Co., Ltd. Arena Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/f8f4ch/arterial About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
VIVUS, Inc. Earnings: What to Expect Monday
Dan Caplinger, The Motley Fool - Motley Fool - Sat Feb 22, 12:45PM CST
VIVUS will release its quarterly report on Monday, and investors haven't been happy with the way that the obesity-drug maker's stock has performed. Despite the huge potential in the obesity-treatment space that sent shares of VIVUS, Arena...
Biotech Showdown: Arena Pharmaceuticals vs. VIVUS Inc.
George Budwell, The Motley Fool - Motley Fool - Thu Feb 20, 8:59AM CST
The obesity-drug space is turning out to be tough sledding for Arena Pharmaceuticals and VIVUS , with both of their respective FDA approved medications failing to meet market expectations in terms of prescription numbers. As a result, shares of...
(0)
(0)Arena Pharmaceuticals (ARNA) Stock Research Links
Scroll down for more posts ▼